Trial Seeks Better Use of Central Lines in Hospitals
The University of Queensland has launched the IVCare trial to investigate the best practices for managing central venous access devices (CVADs). The study aims to reduce complications like infections and blood clots, which currently affect thousands of patients annually.
Why it matters
Improving the safety and efficacy of medical devices used in critical care can significantly reduce hospital costs and improve patient recovery outcomes.
The best methods of preventing infection and complications from central lines will be investigated in a new clinical trial.
Led by The University of Queensland, the IVCare trial will examine central venous access devices (CVADs) that are commonly used in cancer treatment, dialysis and intensive care.
Professor Claire Rickard , of UQ's School of Nursing, Midwifery and Social Work , said CVADs allow medicines and fluids to be given directly into the bloodstream, and blood to be withdrawn for dialysis or blood tests.
"These devices are a type of intravenous (IV) line used by more than 100,000 Australians each year, but complications such as bloodstream infections, catheter dislodgement and blood clots can interrupt therapy, prolong hospitalisation and increase healthcare costs and mortality risk,'' Professor Rickard said.
"Currently, decisions about CVAD products and practices can be influenced by what is available or familiar at an individual hospital.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in